Literature DB >> 15308095

The immunobiology of cancer immunosurveillance and immunoediting.

Gavin P Dunn1, Lloyd J Old, Robert D Schreiber.   

Abstract

The last fifteen years have seen a reemergence of interest in cancer immunosurveillance and a broadening of this concept into one termed cancer immunoediting. The latter, supported by strong experimental data derived from murine tumor models and provocative correlative data obtained by studying human cancer, holds that the immune system not only protects the host against development of primary nonviral cancers but also sculpts tumor immunogenicity. Cancer immunoediting is a process consisting of three phases: elimination (i.e., cancer immunosurveillance), equilibrium, and escape. Herein, we summarize the data supporting the existence of each of the three cancer immunoediting phases. The full understanding of the immunobiology of cancer immunosurveillance and immunoediting will hopefully stimulate development of more effective immunotherapeutic approaches to control and/or eliminate human cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308095     DOI: 10.1016/j.immuni.2004.07.017

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  890 in total

1.  Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.

Authors:  Richard Metz; James B Duhadaway; Sonja Rust; David H Munn; Alexander J Muller; Mario Mautino; George C Prendergast
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

Review 2.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 3.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

4.  Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

Authors:  Courtney A Crane; Brian J Ahn; Seunggu J Han; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

Review 5.  Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases.

Authors:  Paola Nisticò; Mina J Bissell; Derek C Radisky
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

6.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Authors:  Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

7.  miR-155 regulates IFN-γ production in natural killer cells.

Authors:  Rossana Trotta; Li Chen; David Ciarlariello; Srirama Josyula; Charlene Mao; Stefan Costinean; Lianbo Yu; Jonathan P Butchar; Susheela Tridandapani; Carlo M Croce; Michael A Caligiuri
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

8.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

9.  A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Nancy L Bartlett; Alex F Herrera; Eva Domingo-Domenech; Amitkumar Mehta; Andres Forero-Torres; Ramon Garcia-Sanz; Philippe Armand; Sumana Devata; Antonia Rodriguez Izquierdo; Izidore S Lossos; Craig Reeder; Taimur Sher; Robert Chen; Sylvia E Schwarz; Leila Alland; Andras Strassz; Kim Prier; Cassandra Choe-Juliak; Stephen M Ansell
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

10.  Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.

Authors:  Liping Song; Tasnim Ara; Hong-Wei Wu; Chan-Wook Woo; C Patrick Reynolds; Robert C Seeger; Yves A DeClerck; Carol J Thiele; Richard Sposto; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.